Hymenoptera venom immunotherapy

Immunotherapy

Volumn 3, Issue 2, 2011, Pages 229-246

  Bilò, Beatrice M ^a   Bonifazi, Floriano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

build up phase protocol; efficacy; future strategies; indications; mechanisms; recombinant venom allergens; relapse; risk factors; safety venom immunotherapy

Indexed keywords

ADRENALIN; ALLPYRAL; ANTIHISTAMINIC AGENT; BEE VENOM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; LEVOCETIRIZINE; MONTELUKAST; OMALIZUMAB; UNCLASSIFIED DRUG; VESPA CRABRO VENOM; VESPULA VENOM; WASP VENOM;

ALLERGY TEST; ANAMNESIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BEE STING; BUMBLEBEE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL PROTOCOL; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HORNET STING; HUMAN; IMMUNOTHERAPY; INJECTION SITE REACTION; INSECT ALLERGY; INSECT BITE; INSECT STING; MAINTENANCE DRUG DOSE; MASTOCYTOSIS; PRICK TEST; PRIORITY JOURNAL; RADIOALLERGOSORBENT TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENCE RISK; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SERUM SICKNESS; SKIN TEST; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URTICARIA; VESPID STING; YELLOW JACKET STING;

ANAPHYLAXIS; ANIMALS; ARTHROPOD VENOMS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYMENOPTERA; INSECT BITES AND STINGS;

EID: 79951756150     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.88     Document Type: Review

References (131)

1. Bilò BM, Ruëff F, Mosbech H, Bonifazi F, Oude Elberink JNG; the EAACI Interest Group on Insect Venom Hypersensitivity: diagnosis of hymenoptera venom allergy. Allergy 60, 1339-1349 (2005).
2. Muller UR: Insect Sting Allergy. Clinical Picture, Diagnosis and Treatment. Gustav Fischer Verlag, Germany (1990).
3. Bilò BM, Bonifazi F: Epidemiology of insect-venom anaphylaxis. Curr. Opin. Allergy Clin. Immunol. 8, 330-337 (2008).
4. Moffitt JE, Golden DB, Reisman RE et al.: Stinging insect hypersensitivity: a practice parameter update. J. Allergy Clin. Immunol. 114, 869-886 (2004). (Pubitemid 39330260)
5. Golden MD, David BK: Insect sting anaphylaxis. Immunol. Allergy Clin. North Am. 27, 261-272 (2007).
6. Bilò MB, Bonifazi F: The natural history and epidemiology of insect venom allergy: clinical implications. Clin. Exp. Allergy 39, 1467-1476 (2009).
7. Sampson HA, Muñoz-Furlong A, Campbell RL et al.: Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. J. Allergy Clin. Immunol. 117, 391-397 (2006). (Pubitemid 43190153)
8. Graif Y, Romano-Zelekha O, Livne I, Green MS, Shohat T: Allergic reactions to insect stings: results from a national survey of 10,000 junior high school children in Israel. J. Allergy Clin. Immunol. 117, 1435-1439 (2006). (Pubitemid 44208983)
9. Oude Elberink JN, de Monchy JG, Golden DB et al.: Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy. J. Allergy Clin. Immunol. 109, 162-170 (2002). (Pubitemid 34112147)
10. Bonifazi F, Jutel M, Bilò BM et al.; the EAACI Interest Group on Insect Venom Hypersensitivity: Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 60, 1459-1470 (2005). (Pubitemid 41654315)
11. Oude Elberink J, de Monchy J, van der Heide S et al.: Venom immunotherapy improves health related quality of life in patients allergic to yellow jacket venom. J. Allergy Clin. Immunol. 110, 174-182 (2002). (Pubitemid 36132745)
12. Akdis M, Akdis CA: Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 119, 780-791 (2007).
13. Akdis CA, Akdis M, Bleskeen T et al.: Epitope-specific T cell: tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 98, 1676-1683 (1996). (Pubitemid 26327879)
14. Jutel M, Akdis M, Budak F et al.: IL-10 and TGF-b cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33, 1205-1214 (2003). (Pubitemid 36609138)
15. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K: Role of interleukin 10 in specific immunotherapy. J. Clin. Invest.102, 98-106 (1998). (Pubitemid 28323835)
16. Francis JN, Till SJ, Durham SR: Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. 111, 1255-1261 (2003). (Pubitemid 36683679)
17. Akdis M, Blaser K, Akdis CA: T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J. Allergy Clin. Immunol. 116, 961-968 (2005).
18. Ling EM, Smith T, Nguyen XD et al.: Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 363, 608-615 (2004). (Pubitemid 38264178)
19. Mamessier E, Birnbaum J, Dupuy P et al.: Ultrarush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin. Exp. Allergy 36, 704-713 (2006). (Pubitemid 43972965)
20. Wachholz PA, Durham SR: Mechanisms of immunotherapy: IgG revisited. Curr. Opin. Allergy Clin. Immunol. 4, 313-318 (2004). (Pubitemid 39006847)
21. Punnonen J, De Waal Malefyt R, Van Vlasselaer P, Gauchat J-F, De Vries JE: IL-10 and viral IL-10 prevent IL-4-induced IgE synthesis by inhibiting the accessory cell function of monocytes. J. Immunol. 151, 1280-1289 (1993). (Pubitemid 23219264)
22. Jutel M, Akdis M, Blaser K, Akdis CA: Mechanisms of allergen specific immunotherapy - T-cell tolerance and more. Allergy 61, 796-807 (2006). (Pubitemid 43893981)
23. Jutel M, Muller UR, Fricker M et al.: Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin. Exp. Allergy 26, 1112-1118 (1996). (Pubitemid 26354358)
24. Bauer C, Przybilla B, Eberlein B et al.: Changes in intracellular cyclic adenosine monophosphate levels in peripheral blood leukocytes during immunotherapy with vespid venom. Ann. Allergy Asthma Immunol. 98, 281-285 (2007). (Pubitemid 46417575)
25. Ruëff F, Przybilla B, Bil MB et al.: Predictors of severe systemic anaphylactic reactions in patients with hymenoptera venom allergy: importance of baseline serum tryptase - a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J. Allergy Clin. Immunol. 124, 1047-1054 (2009).
26. Goldberg A, Confino-Cohen R: Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. J. Allergy Clin. Immunol. 100, 182-184 (1997). (Pubitemid 27349858)
27. Pantera B, Hoffman DR, Carresi L et al.: Characterization of the major allergens purified from the venom of the paper wasp Polistes gallicus. Biochim. Biophys. Acta 1623, 72-81 (2003). (Pubitemid 37315663)
28. Bilò MB, Bonifazi F: Advances in hymenoptera venom immunotherapy. Curr. Opin. Allergy Clin. Immunol. 7, 567-573 (2007). (Pubitemid 350076455)
29. Hamilton RG: Diagnostic methods for insect sting allergy. Curr. Opin. Allergy Clin. Immunol. 4, 297-306 (2004). (Pubitemid 39006845)
30. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM: Insect sting allergy with negative venom skin test responses. J. Allergy Clin. Immunol. 107, 897-901 (2001). (Pubitemid 32436925)
31. Müller U, Golden DBK, Lockey RF, Shin B: Immunotherapy for hymenoptera venom hypersensitivity. Clin. Allergy Immunol. 21, 377-392 (2008).
32. Hoffman DR: Fatal reactions to hymenoptera stings. Allergy Asthma Proc. 24, 123-127 (2003). (Pubitemid 37034198)
33. Hemmer W, Focke M, Kolarich D et al.: Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging-insect allergy. J. Allergy Clin. Immunol. 108, 1045-1052 (2001). (Pubitemid 33151562)
34. Müller UR, Johansen N, Petersen AB, Fromberg-Nielsen J, Haeberli G: Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5. Allergy 64, 543-548 (2009).
35. Mittermann I, Zidarn M, Silar M et al.: Recombinant allergen-based IgE testing to distinguish bee and wasp allergy. J. Allergy Clin. Immunol. 125, 1300-1307 (2010).
36. Seismann H, Blank S, Cifuentes L et al.: Recombinant phospholipase A1 (Ves v 1) from yellow jacket venom for improved diagnosis of hymenoptera venom hypersensitivity. Clin. Mol. Allergy 8, 7 (2010).
37. Bilò MB, Brianzoni F, Cinti B, Napoli G, Bonifazi F: The dilemma of the negative skin test reactors with a history of venom anaphylaxis: will this always be the case? Eur. Ann. Allergy Clin. Immunol. 37, 341-342 (2005). (Pubitemid 41784179)
38. Guerti K, Bridts CH, Stevens WJ, Ebo DG: Wasp venom-specific IgE: towards a new decision threshold? J. Investig. Allergol. Clin. Immunol. 18, 321-323 (2008). (Pubitemid 352031584)
39. Golden DB, Kelly D, Hamilton RG, Wang NY, Kagey-Sobotka A: Dialyzed venom skin tests for identifying yellow jacket-allergic patients not detected using standard venom. Ann. Allergy Asthma Immunol. 102, 47-50 (2009).
40. Eberlein-König B, Varga R, Mempel M, Darsow U, Behrendt H, Ring J: Comparison of basophil activation tests using CD63 or CD203c expression in patients with insect venom allergy. Allergy 61, 1084-1085 (2006). (Pubitemid 44175215)
41. Ebo DG, Hagendorens MM, Schuerwegh AJ et al.: Flow-assisted quantification of in vitro activated basophils in the diagnosis of wasp venom allergy and follow-up of wasp venom immunotherapy. Cytometry B Clin. Cytom. 72, 196-203 (2007). (Pubitemid 46676752)
42. Scherer K, Weber JM, Jermann TM et al.: Cellular in vitro assays in the diagnosis of Hymenoptera venom allergy. Int. Arch. Allergy Immunol. 146, 122-132 (2008). (Pubitemid 351685475)
43. Korosec P, Erzen R, Silar M, Bajrovic N, Kopac P, Kosnik M: Basophil responsiveness in patients with insect sting allergies and negative venom-specific immunoglobulin E and skin prick test results. Clin. Exp. Allergy 39, 1730-1737 (2009).
44. Kleine-Tebbe J, Erdmann S, Knol EF, MacGlashan DW Jr, Poulsen LK, Gibbs BF: Diagnostic tests based on human basophils: potentials, pitfalls and perspectives. Int. Arch. Allergy Immunol. 141, 79-90 (2006).
45. Przybilla B, Ruëff F: Hymenoptera venom allergy. J. Dtsch Dermatol. Ges. 8, 114-129 (2010).
46. Diwakar L, Noorani S, Huissoon AP, Frew AJ, Krishna MT: Practice of venom immunotherapy in the United Kingdom: a national audit and review of literature. Clin. Exp. Allergy 38, 1651-1658 (2008).
47. Golden DB: Insect sting allergy and venom immunotherapy: a model and a mystery. J. Allergy Clin. Immunol. 115, 439-447 (2005). (Pubitemid 40341690)
48. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM: Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N. Engl. J. Med. 351, 668-674 (2004).
49. Golden DB, Marsh DG, Freidhoff LR et al.: Natural history of Hymenoptera venom sensitivity in adults. J. Allergy Clin. Immunol. 100, 760-766 (1997). (Pubitemid 28298993)
50. Fernandez J, Soriano V, Mayorga L, Mayor M: Natural history of hymenoptera venom allergy in Eastern Spain. Clin. Exp. Allergy 35, 179-185 (2005). (Pubitemid 40353780)
51. Ruëff F, Placzek M, Przybilla B: Mastocytosis and hymenoptera venom allergy. Curr. Opin. Allergy Clin. Immunol. 6, 284-288 (2006). (Pubitemid 44510186)
52. Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN: Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 64, 1237-1245 (2009).
53. Bonadonna P, Perbellini O, Passalacqua G et al.: Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and increased serum tryptase levels. J. Allergy Clin. Immunol. 123, 680-686 (2009).
54. Solley GO: Stinging and biting insect allergy: an Australian experience. Ann. Allergy Asthma Immunol. 93, 532-537 (2004). (Pubitemid 39628274)
55. Antonicelli L, Bilò MB, Napoli G, Farabollini B, Bonifazi F: European hornet (Vespa crabro) sting: a new risk factor for life-threatening reaction in hymenoptera allergic patients? Allerg. Immunol. (Paris) 35, 199-203 (2003). (Pubitemid 36781875)
56. Oude Elberink JN, van der Heide S, Guyatt GH, Dubois AE: Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis. J. Allergy Clin. Immunol. 118, 699-704 (2006). (Pubitemid 44301393)
57. Golden DB, Kelly D, Hamilton RG, Craig TJ: Venom immunotherapy reduces large local reactions to insect stings. J. Allergy Clin. Immunol. 123, 1371-1375 (2009).
58. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E: Standards for practical allergen-specific immunotherapy. Allergy 61(Suppl. 82), 1-20 (2006).
59. Müller UR: Cardiovascular disease and anaphylaxis. Curr. Opin. Allergy Immunol. 7, 337-341 (2007). (Pubitemid 47052022)
60. Müller UR, Haeberli G: Use of b-blockers during immunotherapy for hymenoptera venom allergy. J. Allergy Clin. Immunol. 115, 606-610 (2005). (Pubitemid 40341717)
61. Caviglia AG, Passalacqua G, Senna G: Risk of severe anaphylaxis for patients with hymenoptera venom allergy: are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors? J. Allergy Clin. Immunol. 125, 1171 (2010).
62. Bilò MB, Brianzoni MF, Massaccesi C, Frontini F, Bonifazi F: Venom immunotherapy and neoplasia. Presented at: 29th Congress of the European Academy of Allergy and Clinical Immunology (EAACI). London, UK, 5-9 June 2010.
63. Reisman RE: Venom hypersensitivity. J. Allergy Clin. Immunol. 94, 651-658 (1994). (Pubitemid 124006555)
64. Hamilton RG, Wisenauer JA, Golden DB, Valentine MD, Adkinson NF Jr: Selection of hymenoptera venoms for immunotherapy on the basis of patients IgE antibody cross-reactivity. J. Allergy Clin. Immunol. 92, 651-659 (1993). (Pubitemid 23343772)
65. Severino M, Bonadonna P, Bilò MB et al.: Safety and efficacy of immunotherapy with Polistes dominulus venom: results from a large Italian database. Allergy 64, 1229-1230 (2009).
66. Blanca M, Garcia F, Miranda A et al.: Determination of IgE antibodies to Polistes dominulus, Vespula germanica and Vespa crabro in sera of patients allergic to vespids. Allergy 46, 109-114 (1991).
67. Kosnik M, Korosec P, Silar M, Music E, Erzen R: Wasp venom is appropriate for immunotherapy of patients with allergic reaction to the European hornet sting. Croat. Med. J. 43, 25-27 (2002). (Pubitemid 34157861)
68. de Groot H: Allergy to bumblebees. Curr. Opin. Allergy Clin. Immunol. 6, 294-297 (2006). (Pubitemid 44510188)
69. Brown S, Wiese M, Blackman K, Heddle R: Ant venom immunotherapy: a double blind, placebo-controlled cross-over trial. Lancet 361, 1001-1006 (2003).
70. Fernandez-Melendez S, Miranda A, Garcia-Gonzalez et al.: Anaphylaxis caused by imported red fire ants stings in Malaga, Spain. Investig. Allergol. Clin. Immunol. 17, 48-49 (2007). (Pubitemid 46280161)
71. Ross RN, Nelson HS, Finegold I: Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin. Ther. 22, 351-358 (2000). (Pubitemid 30213141)
72. Müller U, Helbling A, Berchtold E: Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J. Allergy Clin. Immunol. 89, 529-535 (1992).
73. Dubois AE: Mastocytosis and hymenoptera allergy. Curr. Opin. Allergy Clin. Immunol. 4, 291-295 (2004). (Pubitemid 39006844)
74. Oude Elberink JNG, De Monchy JGR, Kors JW et al.: Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J. Allergy Clin. Immunol. 99, 153-154 (1997). (Pubitemid 27074911)
75. Haeberli G, Brönnimann M, Hunziker T, Müller U: Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin. Exp. Allergy 33, 1216-1220 (2003). (Pubitemid 37108524)
76. Roumana A, Pitsios C, Vartholomaios S, Kompoti E, Kontou-Fili K: The safety of initiating hymenoptera immunotherapy at 1 μg of venom extract. J. Allergy Clin. Immunol. 124, 379-381 (2009).
77. Bilò MB, Antonicelli L, Bonifazi F: Purified versus nonpurified venom immunotherapy. Curr. Opin. Allergy Clin. Immunol. 10, 330-336 (2010).
78. Müller UR: Bee venom allergy in beekeepers and their family members. Curr. Opin. Allergy Clin. Immunol. 5, 343-347 (2005). (Pubitemid 41017649)
79. Cavallucci E, Ramondo S, Renzetti A et al.: Maintenance venom immunotherapy administered at a 3-month interval preserves safety and efficacy and improves adherence. J. Investig. Allergol. Clin. Immunol. 20, 63-68 (2010).
80. Baenkler HW, Meusser-Storm S, Eger G: Continuous immunotherapy for hymenoptera venom allergy using 6 month intervals. Allergol. Immunopathol. (Madr.) 33, 7-14 (2005). (Pubitemid 40478098)
81. Goldberg A, Confino-Cohen R: Effectiveness of maintenance bee venom immunotherapy administered at 6-month intervals. Ann. Allergy Asthma Immunol. 99, 352-357 (2007). (Pubitemid 47606138)
82. Mellerup MT, Hahn GW, Poulsen LK, Malling H: Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin. Exp. Allergy 30, 1423-1429 (2000).
83. Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H: Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin. Exp. Allergy 36, 254-260 (2006). (Pubitemid 43344706)
84. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC: The Hymenoptera Venom study. III. Safety of venom immunotherapy. J. Allergy Clin. Immunol. 86, 775-780 (1990).
85. Mosbech H, Muller U: Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy 55, 1005-1010 (2000).
86. Kosnik M, Silar M, Bajrovic N, Music E, Korosec P: High sensitivity of basophils predicts side-effects in venom immunotherapy. Allergy 60, 1401-1406 (2005). (Pubitemid 41476183)
87. Ruëff F, Przybilla B: Venom immunotherapy: adverse reactions and treatment failure. Curr. Opin. Allergy Clin. Immunol. 4, 307-311 (2004). (Pubitemid 39006846)
88. Brehler R, Wolf H, Kütting B, Schnitker J, Luger T: Safety of a 2-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J. Allergy Clin. Immunol. 105, 1231-1235 (2000). (Pubitemid 30418804)
89. Birnbaum J, Ramadour M, Magnan A, Vervloet D: Hymenoptera ultrarush venom immunotherapy (210 min): a safety study and risk factors. Clin. Exp. Allergy 33, 58-64 (2003). (Pubitemid 36114908)
90. Reimers A, Hari Y, Müller U: Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 55, 484-488 (2000). (Pubitemid 30230359)
91. Ruëff F, Przybilla B, Bil MB et al.: Predictors of side effects during the buildup phase of venom immunotherapy for hymenoptera venom allergy: the importance of baseline serum tryptase. J. Allergy Clin. Immunol. 126, 105-111 (2010).
92. Tunon-de-Lara JM, Villanueva P, Marcos M, Taytard A: ACE inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet 340, 908 (1992).
93. White KM, England RW: Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann. Allergy Asthma Immunol. 101, 426-430 (2008).
94. Müller U, Hari Y, Berchtold E: Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J. Allergy Clin. Immunol. 107, 81-86 (2001). (Pubitemid 32105249)
95. Müller UR, Jutel M, Reimers A et al.: Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J. Allergy Clin. Immunol. 122, 1001-1007 (2008).
96. Wöhrl S, Gamper S, Hemmer W, Heinze G, Stingl G, Kinaciyan T: Premedication with montelukast reduces local reactions of allergen immunotherapy. Int. Arch. Allergy Immunol. 144, 137-142 (2007). (Pubitemid 47414328)
97. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P: Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J. Investig. Allergol. Clin. Immunol. 19, 225-229 (2009).
98. Kontou-Fili K: High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 63, 376-378 (2008). (Pubitemid 351224685)
99. Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E: Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J. Investig. Allergol. Clin. Immunol. 18, 225-256 (2008).
100. Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A: Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. J. Allergy Clin. Immunol. 124, 157-161.E1-E32 (2009).
101. Canonica GW, Bousquet J, Casale T et al.: Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 64(Suppl. 91), 1-59 (2009).
102. Severino MG, Cortellini G, Bonadonna P et al.: Sublingual immunotherapy for large local reactions caused by honey bee stings. J. Allergy Clin. Immunol. 122, 44-88 (2008).
103. Ruëff F, Bilò MB, Jutel M, Mosbech H, Müller U, Przybilla B; Interest group on hymenoptera venom allergy of the European Academy of Allergology and Clinical Immunology: sublingual immunotherapy with venom is not recommended for patients with hymenoptera venom allergy. J. Allergy Clin. Immunol. 123, 272-273 (2009).
104. Bilò MB, Severino M, Cilia M et al.: The VISYT trial: venom immunotherapy safety and tolerability with purified vs nonpurified extracts. Ann. Allergy Asthma Immunol. 103, 57-61 (2009).
105. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM: Discontinuing venom immunotherapy: outcome after 5 years. J. Allergy Clin. Immunol. 97, 579-587 (1996). (Pubitemid 26062755)
106. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM: Discontinuing venom immunotherapy: extended observations. J. Allergy Clin. Immunol. 101, 298-305 (1998). (Pubitemid 28146345)
107. Senti G, Johansen P, Oliver R et al.: A cutaneous allergen neutralisation test that correlates with the duration of venom immunotherapy. Int. Arch. Allergy Immunol. 141, 377-383 (2006). (Pubitemid 44783908)
108. Ruëff F, Wolf H, Schnitker J et al.: Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy 59, 589-595 (2004). (Pubitemid 38748057)
109. Peternelj A, Silar M, Erzen R, Kosnik M, Korosec P: Basophil sensitivity in patients not responding to venom immunotherapy. Int. Arch. Allergy Immunol. 146, 248-254 (2008). (Pubitemid 351832468)
110. Erdmann S, Sachs B, Moll-Slodowy, Merk H: CD63 expression on basophils in the diagnosis of wasp venom allergy and for monitoring specific immunotherapy. Allergo J. 12, S55-S57 (2003). (Pubitemid 36389204)
111. Dugas-Breit S, Przybilla B, Dugas M et al.: Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for hymenoptera venom allergy. Clin. Exp. Allergy 40, 643-649 (2010).
112. Ruëff F, Przybilla B, Müller U, Mosbech H: The sting challenge test in hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Allergy 51, 216-225 (1996). (Pubitemid 126439560)
113. Ruëff F, Wenderoth A, Przybilla B: Patients still reacting to a sting challenge while receiving conventional hymenoptera venom immunotherapy are protected by increased venom doses. J. Allergy Clin. Immunol. 108, 1027-1032 (2001). (Pubitemid 33151558)
114. Golden DBK: Discontinuing venom immunotherapy. Curr. Opin. Allergy Clin. Immunol. 1, 353-356 (2001).
115. Lerch E, Müller UR: Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J. Allergy Clin. Immunol. 101, 606-612 (1998).
116. Bilò BM, Brianzoni FM, Napoli G, Bonifazi F: Insect sting anoxic encephalopathy after stopping venom immunotherapy. Allergy 61, 268-269 (2006). (Pubitemid 43381842)
117. Müller U, Berchtold E, Helbling A: Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J. Allergy Clin. Immunol. 87, 702-709 (1991).
118. Reimers A, Muller U: Fatal outcome of a Vespula sting in a patient with mastocytosis after specific immunotherapy with honey bee venom. J. World Allergy (Suppl. 1), 69-70 (2005).
119. Golden DB, Kagey-Sobotka A, Lichtenstein LM: Survey of patients after discontinuing venom immunotherapy. J. Allergy Clin. Immunol. 105, 385-390 (2000). (Pubitemid 30109056)
120. Hafner T, DuBuske L, Kosnik M: Long-term efficacy of venom immunotherapy. Ann. Allergy Asthma Immunol. 100, 162-165 (2008). (Pubitemid 351238552)
121. Müller UR: Recombinant hymenoptera venom allergens. Allergy 57, 570-576 (2002). (Pubitemid 34680789)
122. Blank S, Seismann H, Bockisch B et al.: Identification, recombinant expression, and characterization of the 100 kDa high molecular weight hymenoptera venom allergens Api m 5 and Ves v 3. J. Immunol. 184, 5403-5413 (2010).
123. Müller UR, Akdis CA, Fricker M et al.: Successful immunotherapy with T cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in bee sting allergic patients. J. Allergy Clin. Immunol. 101, 747-754 (1998).
124. Fellrath JM, Kettner A, Dufour N et al.: Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a Phase I trial. J. Allergy Clin. Immunol. 111, 854-861 (2003). (Pubitemid 36470260)
125. Jilek S, Barbey C, Spertini F, Corthesy B: Antigen independent suppression of the allergic immune response to bee venom phospholipase A2 by DNA vaccination in CBA/J mice. Immunology 166, 3612-3621 (2001). (Pubitemid 33117368)
126. Kussebi F, Karamloo F, Rhyner C et al.: A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J. Allergy Clin. Immunol. 115, 323-329 (2005). (Pubitemid 40215096)
127. Karamloo F, Schmid-Grendelmeier P, Kussebi F et al.: Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur. J. Immunol. 35, 3268-3276 (2005). (Pubitemid 41672531)
128. Senti G, Prinz Vavricka BM, Erdmann I et al.: Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc. Natl Acad. Sci. USA 105, 17908-17912 (2008).
129. Senti G, Johansen P, Kündig TM: Intralymphatic immunotherapy. Curr. Opin. Allergy Clin. Immunol. 9, 537-543 (2009).
130. Mueller HL: Diagnosis and treatment of insect sensitivity. J. Asthma Res. 3, 331-333 (1966).
131. Ring J, Messmer K: Incidence and severity of anaphylactioid reactions to colloid volume substitutes. Lancet 1, 466-469 (1977). (Pubitemid 8045131)